Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma.
Weber JS, Hamid O, Chasalow SD, Wu DY, Parker SM, Galbraith S, Gnjatic S, Berman D.
J Immunother. 2012 Jan;35(1):89-97.
Related citations
Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trial.
Thompson JA, Hamid O, Minor D, Amin A, Ron IG, Ridolfi R, Assi H, Berman D, Siegel J, Weber JS.
J Immunother. 2012 Jan;35(1):73-7.
The vaccine-site microenvironment induced by injection of incomplete Freund's adjuvant, with or without melanoma peptides.
Harris RC, Chianese-Bullock KA, Petroni GR, Schaefer JT, Brill LB 2nd, Molhoek KR, Deacon DH, Patterson JW, Slingluff CL Jr.
J Immunother. 2012 Jan;35(1):78-88.
Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma.
Joseph RW, Sullivan RJ, Harrell R, Stemke-Hale K, Panka D, Manoukian G, Percy A, Bassett RL, Ng CS, Radvanyi L, Hwu P, Atkins MB, Davies MA.
J Immunother. 2012 Jan;35(1):66-72.
IFN-conditioned dendritic cells for the therapy of melanoma: what is missing?
Alexandrescu DT, Ichim TE, Riordan NH, Marincola FM, Dasanu CA.
J Immunother. 2011 Oct;34(8):607-609. No abstract available.
Redirected lysis of human melanoma cells by a MCSP/CD3-bispecific BiTE antibody that engages patient-derived T cells.
Torisu-Itakura H, Schoellhammer HF, Sim MS, Irie RF, Hausmann S, Raum T, Baeuerle PA, Morton DL.
J Immunother. 2011 Oct;34(8):597-605.
Interferon-conditioned dendritic cells for melanoma immunotherapy.
Farkas A, Kemény L.
J Immunother. 2011 Oct;34(8):606-7; author reply 607-9. No abstract available.
Error occurred: cannot get document summary
Adeno-associated virus-mediated local delivery of LIGHT suppresses tumorigenesis in a murine cervical cancer model.
Maitituoheti M, Li Y, Wang W, Wang W, Han L, Yang R, Wang T, Wu Z, Ma D, Wang S.
J Immunother. 2011 Oct;34(8):581-7.
A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors.
Weber JS, Vogelzang NJ, Ernstoff MS, Goodman OB, Cranmer LD, Marshall JL, Miles S, Rosario D, Diamond DC, Qiu Z, Obrocea M, Bot A.
J Immunother. 2011 Sep;34(7):556-67.
Identification of an HLA-DPB1*0501 restricted Melan-A/MART-1 epitope recognized by CD4+ T lymphocytes: prevalence for immunotherapy in Asian populations.
Meng Z, Wang Y, Zhang G, Ke Y, Yan Y, Wu L, Huang Q, Zeng G, Wang Y, Ying H, Jiao S.
J Immunother. 2011 Sep;34(7):525-34.
A phase 2 trial of bevacizumab and high-dose interferon alpha 2B in metastatic melanoma.
Grignol VP, Olencki T, Relekar K, Taylor C, Kibler A, Kefauver C, Wei L, Walker MJ, Chen HX, Kendra K, Carson WE 3rd.
J Immunother. 2011 Jul-Aug;34(6):509-15.
Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma.
Wilgenhof S, Van Nuffel AM, Corthals J, Heirman C, Tuyaerts S, Benteyn D, De Coninck A, Van Riet I, Verfaillie G, Vandeloo J, Bonehill A, Thielemans K, Neyns B.
J Immunother. 2011 Jun;34(5):448-56.
Endothelial nitric oxide synthase is a key mediator of interleukin-2-induced hypotension and vascular leak syndrome.
Samlowski WE, Kondapaneni M, Tharkar S, McGregor JR, Laubach VE, Salvemini D.
J Immunother. 2011 Jun;34(5):419-27.
Health-related quality of life before and during adjuvant interferon-α treatment for patients with malignant melanoma (DeCOG-trial).
Ziefle S, Egberts F, Heinze S, Volkenandt M, Schmid-Wendtner M, Tilgen W, Linse R, Boettjer J, Vogt T, Spieth K, Eigentler T, Brockmeyer NH, Heinz A, Hauschild A, Schaefer M.
J Immunother. 2011 May;34(4):403-8.
Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies.
Kerkar SP, Sanchez-Perez L, Yang S, Borman ZA, Muranski P, Ji Y, Chinnasamy D, Kaiser AD, Hinrichs CS, Klebanoff CA, Scott CD, Gattinoni L, Morgan RA, Rosenberg SA, Restifo NP.
J Immunother. 2011 May;34(4):343-52.
Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.
Hernandez-Chacon JA, Li Y, Wu RC, Bernatchez C, Wang Y, Weber JS, Hwu P, Radvanyi LG.
J Immunother. 2011 Apr;34(3):236-50.
Helper activity of natural killer cells during the dendritic cell-mediated induction of melanoma-specific cytotoxic T cells.
Wong JL, Mailliard RB, Moschos SJ, Edington H, Lotze MT, Kirkwood JM, Kalinski P.
J Immunother. 2011 Apr;34(3):270-8.
Combinational therapy of interferon-α and chemotherapy normalizes tumor vasculature by regulating pericytes including the novel marker RGS5 in melanoma.
Liu P, Zhang C, Chen J, Zhang R, Ren J, Huang Y, Zhu F, Li Z, Wu G.
J Immunother. 2011 Apr;34(3):320-6.
Interleukin-28B acts synergistically with cisplatin to suppress the growth of head and neck squamous cell carcinoma.
Yoshimoto K, Kishida T, Nakano H, Matsui M, Shin-Ya M, Shimada T, Nakai S, Imanishi J, Takeuchi M, Hisa Y, Mazda O.
J Immunother. 2011 Mar;34(2):139-48.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on